- Home
- LEU vs LNTH Comparison
LEU vs LNTH Comparison
Compare LEU & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- LNTH
- Stock Information
- Founded
- LEU 1998
- LNTH 1956
- Country
- LEU United States
- LNTH United States
- Employees
- LEU N/A
- LNTH 808
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LEU Industrials
- LNTH Health Care
- Exchange
- LEU Nasdaq
- LNTH Nasdaq
- Market Cap
- LEU 3.1B
- LNTH 3.6B
- IPO Year
- LEU 1998
- LNTH 2015
- Fundamental
- Price
- LEU $222.64
- LNTH $57.20
- Analyst Decision
- LEU Buy
- LNTH Strong Buy
- Analyst Count
- LEU 11
- LNTH 6
- Target Price
- LEU $194.80
- LNTH $114.50
- AVG Volume (30 Days)
- LEU 1.3M
- LNTH 2.0M
- Earning Date
- LEU 08-05-2025
- LNTH 08-06-2025
- Dividend Yield
- LEU N/A
- LNTH N/A
- EPS Growth
- LEU 10.12
- LNTH N/A
- EPS
- LEU 6.16
- LNTH 3.77
- Revenue
- LEU $436,900,000.00
- LNTH $1,520,653,000.00
- Revenue This Year
- LEU N/A
- LNTH $4.57
- Revenue Next Year
- LEU $10.51
- LNTH $9.41
- P/E Ratio
- LEU $36.25
- LNTH $15.16
- Revenue Growth
- LEU 12.72
- LNTH 5.75
- 52 Week Low
- LEU $34.91
- LNTH $47.25
- 52 Week High
- LEU $264.90
- LNTH $118.21
- Technical
- Relative Strength Index (RSI)
- LEU 54.89
- LNTH 30.11
- Support Level
- LEU $192.94
- LNTH $47.25
- Resistance Level
- LEU $264.90
- LNTH $73.72
- Average True Range (ATR)
- LEU 17.90
- LNTH 2.16
- MACD
- LEU -2.87
- LNTH -1.69
- Stochastic Oscillator
- LEU 41.27
- LNTH 37.59
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.